Antibiotic R & D company motif bio will be listed in the UK

Source: Ding Xiangyuan 2015-02-03 motif biological mainly develops various antibiotics The company plans to raise at least 4 million pounds, or even up to 16 million pounds, by listing on the A-share market in London The plan mentioned that in order to deal with the spread of "super bacteria", the market urgently needs new antibiotics, and investors' interest is growing Due to the low return on investment, motif biology has been reluctant to obtain investment through listing for many years, but the realization of the recently improved incentive mechanism has made the company change its strategy The best embodiment of this mechanism is Merck's decision to invest $9.5 billion in December to acquire Cubist Motif Bio said it is holding pre IPO talks with investors and will use investment funds to promote the development of its experimental drugs If motif bio gets an investment of up to £ 16 million, whether actual or floating, the value of the company is expected to reach £ 45-60m The company said its most advanced candidate drug, iraprin, is expected to enter the late phase of phase 3 clinical trials in the second half of this year and may be ready to enter the commercialization phase within three years The company is also working to develop some early stage drugs Motif biology, led by Lumsden, a former Merck executive who was a veterinarian, bought iraprin in a deal with the US company nuprim, which was completed after the company went public with aim Alaprin submitted it to US regulators in 2009, but was rejected Motif believes that the drug can be approved as long as it can solve some shortcomings in the original R & D plan